Core Insights - Neurogene (NASDAQ:NGNE) is actively participating in the H.C. Wainwright Genetic Medicines Virtual Conference, demonstrating its commitment to innovation in genetic medicine [1][2] - The stock rating for NGNE was upgraded to "Buy" by H.C. Wainwright on October 2, 2025, at a price of $20.97, which has led to a subsequent increase in stock price to $26.26, reflecting an approximate 11.89% rise [1][2] - NGNE's stock has shown significant volatility, with trading prices ranging from a low of $23.10 to a high of $27.56 today, indicating active trading and interest in the company [2] Market Performance - Over the past year, NGNE's stock has experienced a high of $74.49 and a low of $6.88, which has influenced investor decisions and market perception [2] - The company's current market capitalization is approximately $374.78 million, with a trading volume of 221,727 shares, suggesting strong investor interest in the genetic medicine sector on the NASDAQ exchange [2]